Showing 1 - 11 results of 11 for search 'Follows, G', query time: 0.04s
Refine Results
-
1
Preclinical modeling of cytosine arabinoside response in Mll-Enl translocator mouse leukemias. by Cano, F, Pannel, R, Follows, G, Rabbitts, T
Published 2008Journal article -
2
Limbic encephalitis associated with antibodies to the NMDA receptor in Hodgkin lymphoma. by Zandi, MS, Irani, SR, Follows, G, Moody, A, Molyneux, P, Vincent, A
Published 2009Journal article -
3
Dynamic variation of CD5 surface expression levels within individual chronic lymphocytic leukemia clones by Bashford-Rogers, R, Palser, A, Hodkinson, C, Baxter, J, Follows, G, Vassiliou, G, Kellam, P
Published 2016Journal article -
4
UK experience of Ofatumumab in refractory B-CLL by Varghese, A, Pattinson, J, Carrington, P, Bloor, A, Follows, G, Hillmen, P, Schuh, A, Chowdhury, O
Published 2011Conference item -
5
-
6
Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. by Oscier, D, Dearden, C, Eren, E, Erem, E, Fegan, C, Follows, G, Hillmen, P, Illidge, T, Matutes, E, Milligan, D, Pettitt, A, Schuh, A, Wimperis, J
Published 2012Journal article -
7
Ofatumumab plus chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukaemia (CLL): results of the phase III study COMPLEMENT 1 (OMB110911; NCRN-... by Hillmen, P, Pettitt, A, Schuh, A, Milligan, D, Bowles, K, Bareford, D, Riaz, J, Follows, G, Rule, S, Wallis, J, Gribben, J, Noble, R, Pocock, C, Lisby, S, Carey, J, Gupta, I, Chang, C, McKeown, A
Published 2014Journal article -
8
NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome by Roberts, C, Love, S, Eyre, T, Clifford, R, Boyle, L, Cabes, M, Schuh, A, Bloor, A, Collins, G, Devereux, S, Follows, G, Fox, C, Gribben, J, Hillmen, P, Hatton, C, Littlewood, T, McCarthy, H, Murray, J, Pettitt, A, Soilleux, E, Stamopoulos, B, Weatherspoon, A
Published 2016Journal article -
9
NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome by Eyre, T, Clifford, R, Bloor, A, Boyle, L, Roberts, C, Cabes, M, Collins, G, Devereux, S, Follows, G, Fox, C, Gribben, J, Hillmen, P, Hatton, C, Littlewood, T, Mccarthy, H, Murray, J, Pettitt, A, Soilleux, E, Stamatopoulos, B, Love, S, Wotherspoon, A, Schuh, A
Published 2016Journal article -
10
Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the... by Pettitt, A, Jackson, R, Carruthers, S, Dodd, J, Dodd, S, Oates, M, Johnson, G, Schuh, A, Matutes, E, Dearden, C, Catovsky, D, Radford, J, Bloor, A, Follows, G, Devereux, S, Kruger, A, Blundell, J, Agrawal, S, Allsup, D, Proctor, S, Heartin, E, Oscier, D, Hamblin, T, Rawstron, A, Hillmen, P
Published 2012Journal article -
11
DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes by Kizhakeyil, A, Zaini, NBM, Poh, ZS, Wong, BHS, Loh, X, Ng, AS, Low, ZS, Prasannan, P, Gong, C, Tan, MGK, Nagarajan, C, Huang, D, Lu, PW, Lim, JQ, Barrans, S, Ong, CK, Lim, ST, Chng, WJ, Follows, G, Hodson, DJ, Du, MQ, Goh, YT, Tan, SH, Grigoropoulos, NF, Verma, NK
Published 2021Journal article